Abstract » Hemophilia is among the commonest bleeding disorders encountered in orthopaedic practice and results from an Xchromosome-linked failure of coagulation factors VIII (hemophilia A) or IX (hemophilia B).
H emophilia is an X-chromosome-linked condition that results in a deficiency of a coagulation factor, either factor VIII (in patients with hemophilia A) or factor IX (in those with hemophilia B) 1 . In moderate and severe cases, the factor deficiency leads to recurrent spontaneous hemarthroses, which, in turn, lead to contractures and early degenerative joint disease. The knee is the commonest joint to be affected by hemophilic arthropathy, and there is now a large body of evidence to guide surgeons in the management of such patients. The aim of this article is to assess the current evidence for surgical interventions in patients with hemophilia, with a special focus on the knee.
General Concepts in Hemophilia and Its Treatment
Hemophilia is one of the commonest bleeding disorders encountered in orthopaedic surgery. It is an X-chromosomelinked recessive condition affecting 1 in 5,000 men. Hemophilia is a disorder of the initiation of coagulation and is due to reductions in the concentrations of, or the presence of a less active version of, 1 of 2 coagulation factors, factor VIII and factor IX. The deficiency of these factors results from a defect in 1 of 2 genes on the X chromosome, F8 (which codes for factor 
VIII) and F9 (which codes for factor IX).
Hemophilia A, the commonest form, is a deficiency of factor VIII, and hemophilia B (previously known as Christmas disease) is a deficiency of factor IX 1 . Given the X-chromosome-linked mode of inheritance, most women with a single copy of the faulty gene are carriers, and most are asymptomatic, although a substantial proportion of women who are heterozygous for hemophilia have at least a mild abnormality of coagulation 1 . The severity of hemophilia is graded according to the amount of the deficient coagulation factor present in the circulation. This is expressed as a percentage (with normal being 100%): mild disease results from a concentration between 5% and 40% of normal, moderate disease results from a concentration of 1% to 5%, and severe disease results from a concentration of ,1%
2 .
Patients with severe disease bleed spontaneously, and in patients with mild and moderate disease, excessive bleeding is observed after minor trauma, a surgical procedure, or dental work. In developed countries (20% to 30% of the world population), the orthopaedic problems of hemophilia have reduced since the introduction of prophylaxis using concentrates of the deficient coagulation factor 3 . The use of prophylaxis has the effect of turning serious hemophilia into a milder form by maintaining the factor level above 1% permanently; doses are titrated to the concentration of factors and the incidence of bleeds 4 . In turn, this has led to a reduction in the number of orthopaedic procedures performed for hemophilia. Tobase et al. reported a dramatic decline in orthopaedic interventions in the first decade of this century in a study of patients enrolled in the U.S. Universal Data Collection program; although 7.2% of patients underwent an orthopaedic intervention in 2000, this fell to just 1.7% in 2010 3 . However, the huge economic cost of primary prophylaxis means that 70% to 80% of the world's hemophiliac population does not have access to such treatment; indeed, some regions of the world do not even have access to treatment with factor concentrate when bleeding occurs. Even in developed countries, although children with hemophilia have an excellent prognosis from the point of view of their musculoskeletal health, there remains a cohort of older adults who continue to face the musculoskeletal consequences of the hemarthroses that they sustained before the advent of modern therapies. The major complication of treatment with coagulation factor concentrates is the generation of inhibitors. These are antibodies that are raised against the coagulation factor concentrate, decreasing the efficacy of treatment and necessitating the use of higher doses of factor concentrate 5 . Although inhibitors are rare in hemophilia B (affecting approximately 3% of patients), they are found in 13% of patients with hemophilia A and up to one-third of patients when the disease is severe 6 . A proportion of these patients can be treated with immune tolerance induction, which involves exposing the patient to prolonged high concentrations of coagulation factors to induce peripheral tolerance 5 .
Although improvements in medical prophylaxis and treatment for hemophilia have improved outcomes and reduced the need for orthopaedic interventions in developed countries 3 , musculoskeletal problems remain common in hemophiliacs. Such is the complexity of managing such patients that they are best approached in the context of a multidisciplinary team, with members from hematology, orthopaedic surgery, physical medicine and rehabilitation, pediatrics, psychology, physiotherapy, and nursing. The correct periprocedural management of these patients is perhaps as important as the procedure itself. The musculoskeletal disease in hemophilia is a result of an inflammatory response within the synovium to the presence of hemoglobin-derived iron in the knee joint (hemophilic synovitis). The inflammation leads to a severe, destructive arthropathy with cartilage destruction and osseous erosions (Figs. 1-A, 1-B, and 1-C). A major feature of the disease is stiffness; over time, severe arthrofibrosis forms, leading to progressive contractures of the joint 7 ( Fig.   2 ). The principle of treatment of hemophilic arthropathy is to prevent hemarthroses (which is largely performed through medical means), to treat the hemarthroses (to prevent the inflammatory response), to treat the synovitis that results from this inflammation, and finally, in cases of severe joint destruction, to effectively reconstruct the joint to facilitate the relief of pain and the restoration of function.
Pediatric Orthopaedic Management of the Knee in Hemophilia
Treatment of Acute Hemarthroses Symptom control in hemophilic arthropathy is best achieved by the prevention and prompt treatment of hemarthroses and the synovitis that results. In the acute setting, hemarthroses should be treated with a single dose of factor concentrate; the European Haemophilia Therapy Standardisation Board (EHTSB) has recommended a dose of 25 to 40 IU/kg of factor VIII in patients with hemophilia A without inhibitors, with an increased dose in patients with posttraumatic bleeds 8 . Analgesia and nonsteroidal antiinflammatory drugs are helpful, but, to our knowledge, there is no evidence base to recommend the use of corticosteroids in the acute setting. The EHTSB has prepared guidelines on the management of acute bleeds in hemophilia and recommends against the use of corticosteroids either orally or by intra-articular injection 8 . There is now good evidence that synovectomy is an effective procedure for the prevention of recurrent hemarthroses in hemophilia, although, to our knowledge, there is little evidence that it prevents the development of secondary arthritis 14 . This latter point is surprising; although it might be 
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expected to slow the development of degenerative change by limiting the exposure of the joint to the high levels of hemosiderin, which is thought to be the cause of degenerative change in hemophilia, all series show the development of degenerative change in spite of synovectomy. The progression of degenerative change may be slowed; none of these studies are comparative, and, although degenerative change is reported in all, it is not clear what degree of degeneration would be expected had synovectomy not been performed. In addition to removing the need for treatment of symptomatic hemarthroses, synovectomy improves knee pain and function and slows the reduction in range of movement and the development of flexion contractures 13, 15 . The reduction in the incidence of hemarthroses and need for subsequent treatment renders synovectomy highly cost-effective 16 .
There are extensive published results to support the use of radiosynovectomy, which is in widespread use across Europe. The largest such study is a retrospective review of 500 cases with a mean follow-up of 18.5 years (range, 0.5 to 38 years) 17 . Both 90 Y (in 64% of cases) and 186 Re (in the remaining 36%) were used. The series involved 192 knees as well as ankles and elbows, and the results were presented for the group overall rather than being classified by joint; however, the size and length of follow-up merit this study's inclusion here. Overall, there was a marked and significant decrease (p , 0.001) in the incidence of hemarthrosis, from a median of 6 (range, 2 to 8) per 6 months before treatment to a median of 1.9 (range, 0 to 2) per 6 months, together with significant reductions in pain and clinical synovitis scores (both p , 0.001). There was no indication that radiographic progression was slowed. One-fifth of patients required 2 injections, and approximately one-tenth of patients required 3 injections; only 6.3% of joints required a surgical procedure, either arthroscopic synovectomy or total knee arthroplasty.
The largest series examining the results of radiosynovectomy for knees alone is that of Turkmen et al. 18 , who examined 82 joints of 67 patients undergoing radiosynovectomy with 90 Y.
As with the study by RodriguezMerchan et al. 17 , all cases were performed under factor coverage. Again, there was a substantial reduction in bleeds, from 12.7 per 6 months before treatment to 0.6 per 6 months following treatment, although no statistical analysis was presented with these figures. No radiographic outcomes were given. Many smaller studies exist that show similar results for radiosynovectomy (Table I) . Radiosynovectomy has been in use for 40 years and, to our knowledge, few major complications have been reported 19 . However, in particular,
given the pediatric population who are most likely to receive radiosynovectomy, there have been concerns regarding the dose of ionizing radiation to which patients are being exposed 19 .
There was a single report of 2 cases of acute lymphocytic leukemia in children , with the number of knees in parentheses. §The values are given as the mean in years. #The other outcome for this study was that 63% of knees had a 5-year survival. **This study had a mixed study population and includes other joints; the follow-up and age were for the whole group inclusive of other joints. † †There was no mean given in this study, so the range was listed here. ‡ ‡Figures were given only in a graph form in this study, so the numbers were estimated. § §The surgical procedure included complete medial and lateral meniscectomy. ##There were excellent patient-reported results in 11 of 22 knees.
with hemophilia who had undergone 32 There are fewer studies on chemical synovectomy. One study 24 showed the outcomes of 72 knees treated with osmic acid, although knees are not reported separately, rendering detailed analysis impossible; another study 25 showed the outcomes of 22 knees using rifampicin (Table I) . Chemical synovectomy has been described in cases in which radiosynovectomy is not available or contraindicated (for instance, in countries where the use of these agents is not allowed in children) 13 . Agents used include osmic acid, oxytetracycline, and rifampicin; in all published reports, it is noted that a painful inflammatory response takes place following chemical synovectomy and a period of immobilization with analgesia is required 13, 24, 25 . On the basis of limited evidence, chemical synovectomy appears effective but less so than radiosynovectomy 24 .
For this reason, together with the need for repeated weekly injections and the degree of postoperative pain, we do not use it in our practice. Several series exist of arthroscopic synovectomy in patients with hemophilia, although many are small series that have short follow-up or include synovectomy in joints other than the knee; these have been excluded from this review 26 synovectomy was found to be more likely to result in a decreased range of movement than the arthroscopic procedure, and patients were discharged from the hospital more quickly and required less coagulation factor infusion with the arthroscopic technique. In our experience, a radiosynovectomy should be performed before any type of surgical synovectomy, given that the nonoperative method is much simpler and easier and has similar results. Although radiosynovectomy can be performed at any age, for practical reasons, we use radiosynovectomy with yttrium-90 in children older than 12 years of age, and we prefer to use arthroscopic synovectomy in children under that age (in this age group, both methods would require anesthesia, removing one of the principal advantages of radiosynovectomy). The dose that we use for knee radiosynovectomy is 185 megabecquerels (MBq). Yttrium-90 is a pure beta-emitter, with therapeutic penetration power of 2.8 mm and a mean half-life of 2.8 days. We do not perform chemical synovectomy because of the need for repeated weekly painful injections.
Management of Flexion Contractures
As a result of repeated hemarthroses, the inflamed synovium of the knee becomes fibrotic, leading to arthrofibrosis, shortening of the muscles surrounding the joint, and progressive and severe contractures 7 . Contractures are common (affecting up to 95% of individuals with hemophilia) and can be disabling, even if the joint surfaces themselves remain intact 36 . Contractions can be acute (neoflexum, ,30 days following an episode of hemarthrosis), semi-acute (paleoflexum, 30 days to 1 year), or chronic (archiflexum, .1 year with established arthropathy) 37 . Limitation of the range of movement can occur at either end of the range, but flexion contractures are most disabling. These can be treated with a number of operative and nonoperative techniques. Physical therapy and rehabilitation are the mainstay of preventative treatment for joint contractures 38 . For minor contractures, physiotherapy may be an effective form of treatment, with techniques including manual traction, muscle strengthening, joint stability, and gait training being helpful 39 . Serial casting is a well-established treatment to improve the state of flexion contractures. Fernandez-Palazzi and Battistella reported a series of 58 patients undergoing serial casting over 4 to 6 weeks 40 . They described an improvement in mean flexion deformity from 42.5°to 9.1°. In the same way, orthoses and splints have been used for the correction of minor deformities 41 .
More severe deformities require soft-tissue procedures such as the release of the hamstrings or posterior capsule to allow full extension 42 . In 1999, Wallny et al. reported a series of 27 patients undergoing hamstring release with or without capsulotomy, describing immediate improvements postoperatively and reporting no complications (with most patients demonstrating full resolution of the contracture). However, long-term results (at a mean follow-up of 12.5 years) demonstrated that only 11 patients maintained their range of movement, with a mean loss of 10°. Five patients deteriorated to the extent that they were worse at the time of the latest follow-up than they were before the operation 43 . Those authors recommended the technique in patients with severe deformities but essentially normal joint surfaces, and total knee arthroplasty in cases with joint degeneration. An alternative to surgical release is injection of botulinum toxin into affected muscles. Daffunchio et al. reported their experience of the use of botulinum toxin in 21 patients with at least a flexion contracture of 10°, refractory to physiotherapy 37 . Both paleoflexum and archiflexum cases were included, and contractures ranged from 10°to .46°. In mild to moderate contractures (those ,45°), significant improvements are described of between 44% and 46% (p 5 0.001 in mild contractures and p 5 0.007 in moderate contractures). In severe cases, there was a mean improvement of 30%, but this did not reach significance. Botulinum toxin is commonly used in patients with muscle spasticity. Therefore, for us, its role in muscle contractures such as those seen in patients with hemophilia is controversial. Soft-tissue releases can be used in conjunction with an external fixator for progressive extension 44 to address severe deformities. In the severest deformities, distal femoral osteotomies have been used to correct sagittal plane deformities, although the published data on such procedures in this patient population are limited. Caviglia et al. described the use of extension supracondylar osteotomies to correct flexion deformities in 19 patients 45 . Although the procedure does not increase the absolute range of movement, it improves function by returning the range that does exist into a more functionally useful position. It should be borne in mind that introducing a deformity to the distal part of the femur will render future total knee arthroplasty more challenging. In most cases, these patients have severe joint degeneration, and it is likely that these patients are more suitably treated with total knee arthroplasty.
Total Knee Arthroplasty in Hemophilia
Patients with hemophilia who deteriorate to the extent of requiring total knee arthroplasty pose particular challenges to the arthroplasty surgeon, the anesthetist, and other clinical teams. Such patients should be managed by a multidisciplinary team in a center with experience of managing the perioperative care of patients with hemophilia 46 . Generally, any major surgical procedure in patients without inhibitors is performed under hemostatic cover with a bolus or continuous infusion of the relevant factor concentrate to prevent major perioperative bleeding 46 . Patients with inhibitors are more likely to bleed and have a higher rate of potential complications such as infection; until relatively recently, major orthopaedic procedures were only rarely performed in this group because of the potential for major bleeding, but new products and protocols have rendered such procedures safer in such patients 47 . Prior to the surgical procedure, patients with inhibitors should be treated with immune tolerance induction or other agents such as rituximab or plasmapheresis to reduce the antibody titer as much as possible to allow emergency treatment with coagulation factors in the event of intraoperative or postoperative bleeding 48 . Bypassing agents such as recombinant factor VIIa (rFVIIa) or activated prothrombin complex concentrates are given as repeated boluses intraoperatively and postoperatively to prevent bleeding complications. In common with total knee arthroplasty performed for other reasons, the use of a multimodal bleeding prevention approach including intra-articular or intravenous tranexamic acid has been introduced to cases performed for hemophilia 49 .
In addition to hematological management, the principal challenges of total knee arthroplasty in patients with hemophilia are technical challenges (in particular, dealing with severe deformities and the need for constrained devices), preventing venous thromboembolism, and managing the risk of periprosthetic joint infection 50 . In the existing series, many of these problems are exacerbated by high rates of uncontrolled human immunodeficiency virus (HIV) infection secondary to the use of pooled blood transfusions in the 1980s. As the effect of this diminishes over time, we will have a truer idea of the rate of success of total knee arthroplasty in this population. However, several series exist that showed excellent results in the medium to long term following total knee arthroplasty in such patients.
Rate of Complications Following Total Knee Arthroplasty in Hemophilia
Cancienne et al. conducted a large database study to assess the rate of complications following total knee arthroplasty in hemophilia 51 . These investigators compared the outcomes of 3,396 patients with hemophilia with those of a matched cohort of 427,132 patients without bleeding disorders, reporting a small but significantly higher rate of perioperative infection in the hemophilia cohort at 3 months (2.0% for the patients with hemophilia and 1.3% for the matched cohort) and 6 months (3.5% for the patients with hemophilia and 2.2% for the matched cohort); the odds ratios (ORs) were 1. Patients with hemophilia were no more likely to report stiffness than controls. In other published series, the rate of infection in hemophilia was consistently higher than that expected from total knee arthroplasty in osteoarthritis; however, the situation appears to be improving, with later series showing lower levels of infection (Table II) . It is not clear whether this is due to a lower proportion of patients with HIV or to an increased awareness of the risk of infection and improvements in prophylaxis.
A separate meta-analysis of 336 total knee arthroplasties showed a rate of infection of 7.1% and hemarthrosis in 7.7% 52 .
Venous thromboembolism is of particular interest in patients with hemophilia, as the bleeding disorder itself may represent a contraindication to thromboprophylaxis 53 38 total knee arthroplasties in 33 patients undergoing ultrasound examination following total knee arthroplasty showed no patients with subclinical venous thromboembolism 55 , and a study of 71 cases of hip and knee arthroplasty showed 1 case of symptomatic venous thromboembolism in a patient who was receiving thromboprophylaxis 56 . This third study, by Perez Botero et al., included a review of the existing literature, encompassing 1,107 joint replacements in 843 patients. Not including 2 asymptomatic venous thromboemboli detected on a screening ultrasound, they reported symptomatic venous thromboembolism in 6 cases, giving an incidence of 0.5% (95% CI, 0.1% to 0.9%) 56 .
Overall, the evidence on venous thromboembolism is inconsistent, and further studies are necessary to define the optimal form of venous thromboembolism prophylaxis in this group of patients. Table II gives details of all studies of total knee arthroplasty in hemophilia comprising at least 10 patients and performed since 2000; a total of 1,026 total knee arthroplasties are reported. In the 8 studies showing revision rates at 10 years, implant survival ranges from 81% to 89%, which is substantially lower than that expected for total knee arthroplasty overall (the National Joint Registry for England, Wales, Northern Ireland and the Isle of Man reported a survival rate of 96.6% [95% CI, 96.5% to 96.7%] for total knee arthroplasty with cemented components, irrespective of diagnosis 57 ). However, the cohort of patients with hemophilia undergoing total knee arthroplasty is younger (with a mean age of 40 years in the studies referenced), and the vast majority of patients are male. The 10-year survival figure given in the same National Joint Registry report for male patients younger than 55 years of age is 91.8% (95% CI, 89.4% to 91.3%), with which the figures for hemophilia compare rather more favorably. Survival in later studies appears to be no better than in previous studies; however, the higher mortality rate in earlier studies due to HIV infection may give a falsely high figure for implant survival. 52 .
Implant Survival and Functional Outcome

Conclusions
The widespread availability of coagulation factor concentrates has improved the long-term function of the knee in patients with hemophilia in the developed world. However, in many countries and communities, severe musculoskeletal complications of hemophilia remain a substantial problem for orthopaedic surgeons; even in developed countries, we continue to treat patients with the long-term consequences of years of hemophilic arthropathy.
There is now an evidence basis for the treatment of the consequences of hemophilia in the knee. In the presence of synovitis (confirmed using ultrasonography or magnetic resonance imaging [MRI] ), the use of radiosynovectomy appears to be safe, with excellent results in terms of short-term symptomatology, although no form of synovectomy has been demonstrated to improve long-term outcomes in terms of progression to symptomatic degenerative arthropathy of the knee. The use of conservative and operative measures to treat contractures can improve the quality of life of patients with hemophilia, and total knee arthroplasty can provide equivalent functional results in hemophilic arthropathy to those reported in degenerative or inflammatory arthritides. The results of total knee arthroplasty in hemophilia will be further improved by the development of better perioperative care, in particular concerning prophylaxis for venous thromboembolism and periprosthetic joint infection.
